Aclaris Therapeutics Statistics Share Statistics Aclaris Therapeutics has 108.28M
shares outstanding. The number of shares has increased by 51.77%
in one year.
Shares Outstanding 108.28M Shares Change (YoY) 51.77% Shares Change (QoQ) 0.34% Owned by Institutions (%) 69.8% Shares Floating 92.29M Failed to Deliver (FTD) Shares 3,244 FTD / Avg. Volume 0.29%
Short Selling Information The latest short interest is 7.78M, so 7.18% of the outstanding
shares have been sold short.
Short Interest 7.78M Short % of Shares Out 7.18% Short % of Float 8.56% Short Ratio (days to cover) 11.24
Valuation Ratios The PE ratio is -1.45 and the forward
PE ratio is -2.74.
Aclaris Therapeutics's PEG ratio is
-0.04.
PE Ratio -1.45 Forward PE -2.74 PS Ratio 10.24 Forward PS 32.4 PB Ratio 1.23 P/FCF Ratio -9.49 PEG Ratio -0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Aclaris Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.99,
with a Debt / Equity ratio of 0.
Current Ratio 3.99 Quick Ratio 3.99 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $306.89K Profits Per Employee $-2.17M Employee Count 61 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 43.86% in the
last 52 weeks. The beta is 0.31, so Aclaris Therapeutics's
price volatility has been higher than the market average.
Beta 0.31 52-Week Price Change 43.86% 50-Day Moving Average 1.53 200-Day Moving Average 1.99 Relative Strength Index (RSI) 58.15 Average Volume (20 Days) 1,112,525
Income Statement In the last 12 months, Aclaris Therapeutics had revenue of 18.72M
and earned -132.06M
in profits. Earnings per share was -1.71.
Revenue 18.72M Gross Profit 3.46M Operating Income -141.93M Net Income -132.06M EBITDA -51.72M EBIT -52.53M Earnings Per Share (EPS) -1.71
Full Income Statement Balance Sheet The company has 24.57M in cash and 0 in
debt, giving a net cash position of 24.57M.
Cash & Cash Equivalents 24.57M Total Debt n/a Net Cash n/a Retained Earnings -902.86M Total Assets 198.09M Working Capital 87.28M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -20.07M
and capital expenditures -121K, giving a free cash flow of -20.2M.
Operating Cash Flow -20.07M Capital Expenditures -121K Free Cash Flow -20.2M FCF Per Share -0.26
Full Cash Flow Statement Margins Gross margin is 18.49%, with operating and profit margins of -758.18% and -705.48%.
Gross Margin 18.49% Operating Margin -758.18% Pretax Margin -705.48% Profit Margin -705.48% EBITDA Margin -276.28% EBIT Margin -758.18% FCF Margin -107.88%
